Julia Rotow, MD, reflects on the latest results of several lines of research in locally advanced and advanced non–small cell lung cancer (NSCLC) presented at ESMO 2023.
Beginning with the KEYNOTE-671 study, Dr Rotow expresses hope that the findings regarding pembrolizumab plus chemotherapy will lead to wider adoption of that regimen among patients and clinicians. In the EGFR setting, data from the PAPILLON trial now offer the prospect of improved outcomes for patients with EGFR exon 20 insertion–mutated advanced NSCLC. Dr Rotow concludes by noting exciting data demonstrating central nervous system activity with antibody-drug conjugates, as well as early signs of efficacy in the setting of KRAS-mutant NSCLC, particularly non-G12C mutations.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ESMO 2023: Reflecting on New Data in Advanced NSCLC - Medscape - Nov 13, 2023.
Comments